Abstract

We previously reported that TR2 and TR4 orphan nuclear receptors bind to direct repeat (DR) elements in the ε- and γ-globin promoters, and act as molecular anchors for the recruitment of epigenetic corepressors of the multifaceted DRED complex, thereby leading to ε- and γ-globin transcriptional repression during definitive erythropoiesis. Other than the ε- and γ-globin and the GATA1 genes, TR4-regulated target genes in human erythroid cells remain unknown. Here, we identified TR4 binding sites genome-wide using chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq) as human primary CD34+ hematopoietic progenitors differentiated progressively to late erythroid precursors. We also performed whole transcriptome analyses by RNA-seq to identify TR4 downstream targets after lentiviral-mediated TR4 shRNA knockdown in erythroid cells. Analyses from combined ChIP-seq and RNA-seq datasets indicate that DR1 motifs are more prevalent in the proximal promoters of TR4 direct target genes, which are involved in basic biological functions (e.g., mRNA processing, ribosomal assembly, RNA splicing and primary metabolic processes). In contrast, other non-DR1 repeat motifs (DR4, ER6 and IR1) are more prevalent at gene-distal TR4 binding sites. Of these, approximately 50% are also marked with epigenetic chromatin signatures (such as P300, H3K27ac, H3K4me1 and H3K27me3) associated with enhancer function. Thus, we hypothesize that TR4 regulates gene transcription via gene-proximal DR1 sites as TR4/TR2 heterodimers, while it can associate with novel nuclear receptor partners (such as RXR) to bind to distant non-DR1 consensus sites. In summary, this study reveals that the TR4 regulatory network is far more complex than previously appreciated and that TR4 regulates basic, essential biological processes during the terminal differentiation of human erythroid cells.

Highlights

  • Sickle cell disease (SCD) is an inherited blood disorder caused by a missense mutation in the adult b-globin gene and affects 70,000–90,000 people in the United States and millions worldwide [1,2]

  • Using adult murine erythroleukemia (MEL) nuclear cell extracts, we identified the orphan nuclear receptors TR2 (NR2C1) and TR4 (NR2C2) that as a heterodimer was capable of preferential high-affinity binding to the e- and cglobin direct repeat 1 (DR1) elements and of recruiting chromatin modifying cofactors to those binding sites [10,11]

  • We report the binding of an ‘‘orphan’’ nuclear receptor to its cognate genomic regulatory sites and perform the functional analysis to validate its downstream targets as precursor cells differentiate from very early human hematopoietic progenitors into red blood cells

Read more

Summary

Introduction

Sickle cell disease (SCD) is an inherited blood disorder caused by a missense mutation in the adult b-globin gene and affects 70,000–90,000 people in the United States and millions worldwide [1,2]. For the past three decades, the scientific community has made concerted efforts to develop strategies by which we might safely and efficiently induce HbF synthesis in adult definitive erythroid cells as a potential therapy to treat SCD. Using adult (definitive) murine erythroleukemia (MEL) nuclear cell extracts, we identified the orphan nuclear receptors TR2 (NR2C1) and TR4 (NR2C2) that as a heterodimer was capable of preferential high-affinity binding to the e- and cglobin DR1 elements and of recruiting chromatin modifying cofactors to those binding sites [10,11]. The TR2/TR4 heterodimer mediates e- and c-globin gene silencing through essential DR1 elements in the e- and c-globin promoters in definitive red cells. It would be important to identify the array of TR4 target genes and the physiological functions they participate in during human erythroid differentiation

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.